JP6224690B2 - 抗腫瘍薬の投与方法 - Google Patents

抗腫瘍薬の投与方法 Download PDF

Info

Publication number
JP6224690B2
JP6224690B2 JP2015500851A JP2015500851A JP6224690B2 JP 6224690 B2 JP6224690 B2 JP 6224690B2 JP 2015500851 A JP2015500851 A JP 2015500851A JP 2015500851 A JP2015500851 A JP 2015500851A JP 6224690 B2 JP6224690 B2 JP 6224690B2
Authority
JP
Japan
Prior art keywords
day
days
compound
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015500851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510906A (ja
Inventor
ケリー グレン，
ケリー グレン，
ブライアン ヒギンス，
ブライアン ヒギンス，
グウェン ニコルズ，
グウェン ニコルズ，
キャスリン イー． パックマン，
キャスリン イー． パックマン，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2015510906A publication Critical patent/JP2015510906A/ja
Application granted granted Critical
Publication of JP6224690B2 publication Critical patent/JP6224690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015500851A 2012-03-19 2013-03-15 抗腫瘍薬の投与方法 Active JP6224690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612429P 2012-03-19 2012-03-19
US61/612,429 2012-03-19
PCT/EP2013/055324 WO2013139687A1 (en) 2012-03-19 2013-03-15 Method for administration of an anti tumor agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016197838A Division JP2017061461A (ja) 2012-03-19 2016-10-06 抗腫瘍薬の投与方法

Publications (2)

Publication Number Publication Date
JP2015510906A JP2015510906A (ja) 2015-04-13
JP6224690B2 true JP6224690B2 (ja) 2017-11-01

Family

ID=47913395

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015500851A Active JP6224690B2 (ja) 2012-03-19 2013-03-15 抗腫瘍薬の投与方法
JP2016197838A Pending JP2017061461A (ja) 2012-03-19 2016-10-06 抗腫瘍薬の投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016197838A Pending JP2017061461A (ja) 2012-03-19 2016-10-06 抗腫瘍薬の投与方法

Country Status (21)

Country Link
US (4) US20130245089A1 (https=)
EP (1) EP2827858B1 (https=)
JP (2) JP6224690B2 (https=)
KR (4) KR102438597B1 (https=)
CN (2) CN104203232A (https=)
BR (1) BR112014018135A8 (https=)
CA (1) CA2859940C (https=)
CY (1) CY1118070T1 (https=)
DK (1) DK2827858T3 (https=)
ES (1) ES2593066T3 (https=)
HK (1) HK1204934A1 (https=)
HR (1) HRP20161295T1 (https=)
HU (1) HUE029933T2 (https=)
LT (1) LT2827858T (https=)
MX (1) MX356948B (https=)
PL (1) PL2827858T3 (https=)
PT (1) PT2827858T (https=)
RS (1) RS55250B1 (https=)
RU (1) RU2638795C2 (https=)
SI (1) SI2827858T1 (https=)
WO (1) WO2013139687A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112353762A (zh) * 2013-01-22 2021-02-12 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
EP3459933B1 (en) 2014-04-15 2022-08-24 F. Hoffmann-La Roche AG Solid forms of a pharmaceutically active compound
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
MX388093B (es) 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.
US20210122831A1 (en) 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
CA3052543A1 (en) 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
TWI791794B (zh) 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595107A (zh) * 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
CY1118070T1 (el) 2017-06-28
ES2593066T3 (es) 2016-12-05
EP2827858A1 (en) 2015-01-28
EP2827858B1 (en) 2016-07-20
BR112014018135A2 (https=) 2017-06-20
KR20210016073A (ko) 2021-02-10
KR102438597B1 (ko) 2022-08-31
US20190328708A1 (en) 2019-10-31
PT2827858T (pt) 2016-09-23
MX2014010586A (es) 2014-09-18
DK2827858T3 (en) 2016-08-22
JP2015510906A (ja) 2015-04-13
HRP20161295T1 (hr) 2016-11-18
US11738003B2 (en) 2023-08-29
CN104203232A (zh) 2014-12-10
BR112014018135A8 (pt) 2021-10-19
HK1204934A1 (en) 2015-12-11
HUE029933T2 (en) 2017-04-28
WO2013139687A1 (en) 2013-09-26
KR20190035957A (ko) 2019-04-03
JP2017061461A (ja) 2017-03-30
PL2827858T3 (pl) 2017-01-31
RU2638795C2 (ru) 2017-12-15
LT2827858T (lt) 2016-10-10
CN110013478A (zh) 2019-07-16
KR20140133583A (ko) 2014-11-19
RS55250B1 (sr) 2017-02-28
RU2014141365A (ru) 2016-05-10
MX356948B (es) 2018-06-20
KR20160089549A (ko) 2016-07-27
US20210069149A1 (en) 2021-03-11
SI2827858T1 (sl) 2016-11-30
US20150126575A1 (en) 2015-05-07
CA2859940C (en) 2020-03-24
US20130245089A1 (en) 2013-09-19
CA2859940A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
JP6224690B2 (ja) 抗腫瘍薬の投与方法
ES3036485T3 (en) Combination comprising everolimus and amcenestrant
CN107714684A (zh) 包含α‑甲基‑DL‑酪氨酸的药物组合物及其应用
RU2012128109A (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
Liu et al. Protection effect of curcumin for macrophage-involved polyethylene wear particle-induced inflammatory osteolysis by increasing the cholesterol efflux
Wypij et al. Pamidronate disodium for palliative therapy of feline bone‐invasive tumors
TWI707681B (zh) 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
JP2009539774A (ja) 薬物の投与方法
US11382892B2 (en) Method for administration
HK40011479A (en) Method for administration of an anti-tumor agent
Carlino et al. Effects of intravenous zoledronic acid following subcutaneous teriparatide [(1–34) PTH] in postmenopausal osteoporosis
TWI538672B (zh) 應用二甲雙胍與丁酸鈉於ｋｒａｓ基因突變癌症治療之用途、醫藥組合物與醫藥套組
Wong et al. ED-38an Updated Analysis Of Patient Registry Data On Novottf-100a Alternating Electric Fields Therapy For Recurrent Glioblastoma
Kasumi et al. In vitro effects of a phosphodiesterase inhibitor sildenafil on cellular motility of the oral malignant melanoma cells
Nicoderm extended-duration transdermal nicotine therapy increases abstinence from tobacco
Hörmann Caphosol Mundspülung zur Therapie der Chemotherapie-induzierten oralen Mukositis: eine retrospektive Kohortenstudie
UA55302C2 (en) Tablets intended for treating cancer patients, method for their manufacture, and method for treating cancer patients
Mukohara et al. 421 POSTER Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour
UA118896U (uk) СПОСІБ РАДІОНУКЛІДНО-МЕДИКАМЕНТОЗНОЇ ТЕРАПІЇ ХВОРИХ НА РАК ПЕРЕДМІХУРОВОЇ ЗАЛОЗИ З МНОЖИННИМИ МЕТАСТАЗАМИ В СКЕЛЕТ ІЗ ЗАСТОСУВАННЯМ 153Sm-ОКСАБІФОРУ
WO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171005

R150 Certificate of patent or registration of utility model

Ref document number: 6224690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250